ES2255325T3 - Vacunas mejoradas. - Google Patents

Vacunas mejoradas.

Info

Publication number
ES2255325T3
ES2255325T3 ES99963705T ES99963705T ES2255325T3 ES 2255325 T3 ES2255325 T3 ES 2255325T3 ES 99963705 T ES99963705 T ES 99963705T ES 99963705 T ES99963705 T ES 99963705T ES 2255325 T3 ES2255325 T3 ES 2255325T3
Authority
ES
Spain
Prior art keywords
ige
mammal
immunogenic
polypeptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99963705T
Other languages
English (en)
Spanish (es)
Inventor
Lars T. Hellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Resistentia Pharmaceuticals AB
Original Assignee
Resistentia Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals AB filed Critical Resistentia Pharmaceuticals AB
Application granted granted Critical
Publication of ES2255325T3 publication Critical patent/ES2255325T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES99963705T 1998-11-02 1999-10-21 Vacunas mejoradas. Expired - Lifetime ES2255325T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US106652P 1998-11-02
US401636 1999-09-22
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses

Publications (1)

Publication Number Publication Date
ES2255325T3 true ES2255325T3 (es) 2006-06-16

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99963705T Expired - Lifetime ES2255325T3 (es) 1998-11-02 1999-10-21 Vacunas mejoradas.

Country Status (17)

Country Link
US (3) US6913749B2 (enExample)
EP (1) EP1135158B1 (enExample)
JP (2) JP4205861B2 (enExample)
KR (1) KR100559918B1 (enExample)
AT (1) ATE314087T1 (enExample)
AU (1) AU771889B2 (enExample)
CA (1) CA2348756A1 (enExample)
DE (1) DE69929240T2 (enExample)
DK (1) DK1135158T3 (enExample)
ES (1) ES2255325T3 (enExample)
HU (1) HUP0105392A3 (enExample)
IL (1) IL142582A0 (enExample)
NO (1) NO20012135L (enExample)
NZ (1) NZ511079A (enExample)
PL (1) PL348611A1 (enExample)
PT (1) PT1135158E (enExample)
WO (1) WO2000025722A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2065052A3 (en) * 2000-08-30 2009-08-19 Pfizer Products Inc. Anti-IgE vaccines
EP1330263A2 (en) * 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
ES2306771T3 (es) 2001-02-20 2008-11-16 Ortho Mcneil Pharm Inc Un metodo de terapia celular para tratamiento de tumores.
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ATE438710T1 (de) * 2001-05-15 2009-08-15 Ortho Mcneil Janssen Pharm Ex-vivo-priming zur erzeugung cd40-ligand spezifischer zytotoxischer t-lymphozyten zur behandlung von autoimmun- und allergischen erkrankungen
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
WO2003096966A2 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
ES2316780T3 (es) * 2002-09-05 2009-04-16 Resistentia Pharmaceuticals Ab Vacunas contra alergia.
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
BRPI0922561A2 (pt) 2008-12-09 2020-08-11 Pfizer Vaccines Llc vacina de peptídeo de ch3 da ige.
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN104395337A (zh) * 2012-06-18 2015-03-04 日本全药工业株式会社 IgE肽疫苗
JP2019509059A (ja) 2016-02-16 2019-04-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異型キヌレニナーゼ遺伝子を有する非ヒト動物
ES3031566T3 (en) 2019-06-24 2025-07-09 Univ Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
EP0617127A1 (en) 1987-12-31 1994-09-28 Tanox Biosystems, Inc. Antigenic epitopes on B cell-bound IgE Immunoglobulins
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
DE69126607T2 (de) 1990-01-23 1998-01-15 Tanox Biosystems, Inc., Houston, Tex. Extrazelluläre teilstücke humaner ige-immunoglobulin-ankerpeptide und dafür spezifische antikörper
JPH05508835A (ja) 1990-05-25 1993-12-09 ペプチド・セラピューティクス・リミテッド 慢性関節リウマチの免疫診断検定法
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
EP0662085A1 (en) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) * 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
WO1995026365A1 (en) 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
EP0787150A1 (en) 1994-10-25 1997-08-06 United Biomedical, Inc. SYNTHETIC IgE MEMBRANE ANCHOR PEPTIDE IMMUNOGENS FOR THE TREATMENT OF ALLERGY
GB9422294D0 (en) 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
DE69633623T2 (de) 1995-07-17 2005-12-01 Medivir Uk Ltd. Cystein-Protease-Inhibitoren für die Behandlung von allergischen Krankheiten verursacht duch IgE
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
TR199801722T2 (xx) 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
CA2262001C (en) 1996-08-05 2003-05-20 President And Fellows Of Harvard College Mhc binding peptide oligomers and methods of use
NZ337955A (en) 1997-04-15 2000-09-29 Ferring Farma Lab Modified TNF-alpha and their use as vaccines
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
EP1053343A2 (en) 1998-02-11 2000-11-22 Maxygen, Inc. Targeting of genetic vaccine vectors
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
KR100731820B1 (ko) 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
EE200100552A (et) 1999-04-23 2002-12-16 Pharmexa A/S Meetod kasvuteguri IL-5 aktiivsuse in vivo mahasurumiseks, IL-5 analoog, seda kodeeriv nukleiinhappefragment ning kasutamine immunogeense kompositsiooni valmistamiseks
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP1330263A2 (en) 2000-09-06 2003-07-30 Pharmexa A/S Method for down-regulating ige
CN1541266A (zh) 2001-06-15 2004-10-27 唐诚公司 用于治疗过敏症及哮喘病的Fcε融合蛋白

Also Published As

Publication number Publication date
PL348611A1 (en) 2002-06-03
NZ511079A (en) 2003-08-29
JP2006068015A (ja) 2006-03-16
WO2000025722A2 (en) 2000-05-11
IL142582A0 (en) 2002-03-10
HK1042844A1 (en) 2002-08-30
KR100559918B1 (ko) 2006-03-13
US20040076625A1 (en) 2004-04-22
DK1135158T3 (da) 2006-05-15
JP4205861B2 (ja) 2009-01-07
US7459158B2 (en) 2008-12-02
KR20010089364A (ko) 2001-10-06
DE69929240T2 (de) 2006-08-31
NO20012135D0 (no) 2001-04-30
US20010038843A1 (en) 2001-11-08
ATE314087T1 (de) 2006-01-15
DE69929240D1 (de) 2006-02-02
HUP0105392A3 (en) 2008-04-28
AU771889B2 (en) 2004-04-08
NO20012135L (no) 2001-06-25
WO2000025722A3 (en) 2000-10-12
US6913749B2 (en) 2005-07-05
CA2348756A1 (en) 2000-05-11
PT1135158E (pt) 2006-05-31
EP1135158B1 (en) 2005-12-28
JP4188353B2 (ja) 2008-11-26
US20030031663A1 (en) 2003-02-13
AU2008100A (en) 2000-05-22
JP2002531064A (ja) 2002-09-24
HUP0105392A2 (hu) 2002-04-29
EP1135158A2 (en) 2001-09-26

Similar Documents

Publication Publication Date Title
EP1135158B1 (en) Enhanced vaccines based on chimeric immunoglobulin e peptides
ES2144424T5 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
ES2318006T3 (es) Anticuerpos humanizados que reconocen el peptido beta-amiloide.
ES2312569T3 (es) Anticuerpos humanizados.
ES2962794T3 (es) Cisteina proteasa
KR100308444B1 (ko) 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해항체반응을유도하는방법
ES2550099T3 (es) Antagonistas del receptor Nogo
ES2362386T3 (es) Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro.
BR112019026803A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
ES2427147T3 (es) Anticuerpo sHlgM12 útil para tratar esclerosis múltiple
BR112019026907A2 (pt) Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos
ES2438444T3 (es) Variantes de la familia de IL-1
JPH04504424A (ja) 膜結合ＩｇＡに存在するが分泌ＩｇＡに存在しない抗原エピトープ
BRPI0609100A2 (pt) conjugado para alvejamento de fármaco, método de produzir o referido conjugado, bem como composição contendo o mesmo
CN108602857A (zh) 重组IgG Fc多聚体
JP2012214477A (ja) 抗原およびＥＢＶＧｐ３５０／２２０の受容体の同時刺激によるＢ細胞活性化および免疫グロブリン分泌の増強
BR112020012554A2 (pt) anticorpos de cadeia pesada que se ligam a cd22
ES2806205T3 (es) Cadena alfa del receptor de IgE de alta afinidad de fusión Fc
US20100021486A1 (en) Tslp vaccine for the treatment of th2 mediated inflammatory conditions
SG11202106128TA (en) Anti-il-17a antibody and use thereof
RU2214279C2 (ru) Усовершенствованные вакцины
ES2316780T3 (es) Vacunas contra alergia.
WO2008066443A1 (en) Il-33 vaccine for the treatment of inflammatory conditions with a strong th2 component
EP1621209A2 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
HK1042844B (en) Enhanced vaccines based on chimeric immunoglobulin e peptides